备孕期高血压的规范管理

doi:10.12114/j.issn.1007-9572.2022.0854

摘要/Abstract

摘要： 近年来由于生活压力的增加，我国越来越多的育龄期男女罹患高血压，因此如何规范管理备孕期高血压已成为当前的焦点。本文从备孕期间血压的监测与评估和降压药的使用两方面分别对育龄期男性和女性备孕期间的血压规范管理进行阐述，强调女性备孕期间的高血压管理应同时考虑母体和胎儿的安全性，选择相对安全的降压药，如甲基多巴、拉贝洛尔、硝苯地平等；男性备孕期间的高血压管理应同时考虑降压药的疗效及其对性功能和精子的影响，推荐奈必洛尔、血管紧张素转换酶抑制剂（ACEI）/血管紧张素Ⅱ受体拮抗剂（ARB）和钙离子通道阻滞剂（CCB）类药物，旨在为临床备孕期高血压的管理提供指导并为未来研究提供参考方向。

关键词: 高血压, 怀孕，计划, 孕前保健, 备孕期, 疾病管理, 规范管理, 生殖

Abstract:

In recent years, due to the increase of life stress, there is an increasing number of the men and women of childbearing age suffering from hypertension in China. Therefore, the standardized management of hypertension during the preparation for pregnancy has become a current focus. The standardized management of blood pressure of males and females of childbearing age during pregnancy preparation was discussed in this paper in terms of both monitoring and evaluating of hypertension during the preparation for pregnancy and application of antihypertensive drugs, emphasizing that the management of hypertension during pregnancy preparation in women should consider both maternal and fetal safety, choose relatively safe antihypertensive drugs such as methyldopa, labetalol, nifedipine, etc; the management of hypertension during pregnancy preparation in men should consider the efficacy of antihypertensive drugs and the effects on sexual function and sperm, Nebivolol, ACEI/ARB and CCB drugs are recommended, in order to provide guidance for the management of hypertension during the preparation for pregnancy reference direction for future research.

Key words: Hypertension, Pregnancy, planned, Preconception care, Preparation for pregnancy, Disease management, Standardized management, Reproduction

田梅香,张正义. 备孕期高血压的规范管理[J]. 中国全科医学, 2023, 26(18): 2190-2194. DOI: 10.12114/j.issn.1007-9572.2022.0854.
TIAN Meixiang,ZHANG Zhengyi. Standard Management of Hypertension During the Preparation for Pregnancy[J]. Chinese General Practice, 2023, 26(18): 2190-2194. DOI: 10.12114/j.issn.1007-9572.2022.0854.

参考文献 39

[1]	Al-MAKKI A, DIPETTE D, WHELTON P K，et al. Hypertension pharmacological treatment in adults：a World Health Organization guideline executive summary[J]. Hypertension，2022，79(1):293-301. DOI：10.1161/HYPERTENSIONAHA.121.18192.
[2]	AKBAR M I A, ADIBRATA M A, ADITIAWARMAN，et al. Maternal and perinatal outcome related to severity of chronic hypertension in pregnancy[J]. Pregnancy Hypertens，2019，16:154-160. DOI：10.1016/j.preghy.2019.04.007.
[3]	中华医学会妇产科学分会妊娠期高血压疾病学组. 妊娠期高血压疾病诊治指南（2015）[J]. 中华围产医学杂志，2016，19(3):161-169. DOI：10.3760/cma.j.issn.1007-9408.2016.03.001.
[4]	GREENBERG V R, SILASI M, LUNDSBERG L S，et al. Perinatal outcomes in women with elevated blood pressure and stage 1 hypertension[J]. Am J Obstet Gynecol，2021，224(5):521.e1-521521.e11. DOI：10.1016/j.ajog.2020.10.049.
[5]	HERNÁNDEZ-CERDA J, BERTOMEU-GONZÁLEZ V, ZUAZOLA P，et al. Understanding erectile dysfunction in hypertensive patients: the need for good patient management[J]. Vasc Health Risk Manag，2020，16:231-239. DOI：10.2147/VHRM.S223331.
[6]	FARMAKIS I T, PYRGIDIS N, DOUNDOULAKIS I，et al. Effects of major antihypertensive drug classes on erectile function: a network meta-analysis[J]. Cardiovasc Drugs Ther，2022，36(5):903-914. DOI：10.1007/s10557-021-07197-9.
[7]	DELKER E, BANDOLI G, LACOURSIERE Y，et al. Chronic hypertension and risk of preterm delivery: national longitudinal study of adolescents to adult health[J]. Paediatr Perinat Epidemiol，2022，36(3):370-379. DOI：10.1111/ppe.12858.
[8]	LU Y, CHEN R F, CAI J J，et al. The management of hypertension in women planning for pregnancy[J]. Br Med Bull，2018，128(1):75-84. DOI：10.1093/bmb/ldy035.
[9]	AN H, CHEN H T, LI Z W，et al. Association of preconception blood pressure with the risk of anemia in children under five years of age: a large longitudinal Chinese birth cohort[J]. Nutrients，2022，14(13):2640. DOI：10.3390/nu14132640.
[10]	中华医学会心血管病学分会女性心脏健康学组，中华医学会心血管病学分会高血压学组. 妊娠期高血压疾病血压管理专家共识（2019）[J]. 中华心血管病杂志，2020，48(3):195-204. DOI：10.3760/cma.j.cn112148-20191024-00652.
[11]	UNGER T, BORGHI C, CHARCHAR F，et al. 2020 International Society of Hypertension global hypertension practice guidelines[J]. J Hypertens，2020，38(6):982-1004. DOI：10.1097/HJH.0000000000002453.
[12]	RABI D M, MCBRIEN K A, SAPIR-PICHHADZE R，et al. Hypertension Canada's 2020 comprehensive guidelines for the prevention，diagnosis，risk assessment，and treatment of hypertension in adults and children[J]. Can J Cardiol，2020，6(5):596-624. DOI：10.1016/j.cjca.2020.02.086.
[13]	AGRAWAL A, WENGER N K. Hypertension during pregnancy[J]. Curr Hypertens Rep，2020，22(9):64. DOI：10.1007/s11906-020-01070-0.
[14]	MAGEE L A, VON DADELSZEN P, REY E，et al. Less-tight versus tight control of hypertension in pregnancy[J]. N Engl J Med，2015，372(5):407-417. DOI：10.1056/NEJMoa1404595.
[15]	ABE M, ARIMA H, YOSHIDA Y，et al. Optimal blood pressure target to prevent severe hypertension in pregnancy: a systematic review and meta-analysis[J]. Hypertens Res，2022，45(5):887-899. DOI：10.1038/s41440-022-00853-z.
[16]	BROWN M A, MAGEE L A, KENNY L C，et al. Hypertensive disorders of pregnancy: ISSHP classification，diagnosis，and management recommendations for international practice[J]. Hypertension，2018，72(1):24-43. DOI：10.1161/HYPERTENSIONAHA.117.10803.
[17]	WILLIAMS B, MANCIA G, SPIERING W，et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension[J]. Eur Heart J，2018，39(33):3021-3104. DOI：10.1093/eurheartj/ehy339.
[18]	BELLOS I, PERGIALIOTIS V, PAPAPANAGIOTOU A，et al. Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network metaanalysis[J]. Am J Obstet Gynecol，2020，223(4):525-537. DOI：10.1016/j.ajog.2020.03.016.
[19]	ABALOS E, DULEY L, STEYN D W，et al. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy[J]. Cochrane Database Syst Rev，2018，10(10):CD002252. DOI：10.1002/14651858.CD002252.pub4.
[20]	杨宁. 待孕育高血压患者血压管理及降压药物选择[J]. 中国循环杂志，2017，32(8):820-822. DOI：10.3969/j.issn.1000-3614.2017.08.022.
[21]	WHITE B M, ANDERSON S L, MARRS J C. Antihypertensive prescribing patterns and hypertension control in females of childbearing age[J]. Am J Health Syst Pharm，2021，78(14):1317-1322. DOI：10.1093/ajhp/zxab162.
[22]	AMRO F, SIBAI B. Management of hypertension in pregnancy[J]. Semin Fetal Neonatal Med，2020，25(5):101147. DOI：10.1016/j.siny.2020.101147.
[23]	FU J, TOMLINSON G, FEIG D S. Increased risk of major congenital malformations in early pregnancy use of angiotensin-converting-enzyme inhibitors and angiotensin-receptor-blockers: a meta-analysis[J]. Diabetes Metab Res Rev，2021，37(8):e3453. DOI：10.1002/dmrr.3453.
[24]	MAGEE L A, KHALIL A, KAMETAS N，et al. Toward personalized management of chronic hypertension in pregnancy[J]. Am J Obstet Gynecol，2022，226(2S):S1196-1210. DOI：10.1016/j.ajog.2020.07.026.
[25]	American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 203: Chronic Hypertension in Pregnancy[J]. Obstet Gynecol，2019，133(1):e26-50. DOI：10.1097/AOG.0000000000003020.
[26]	SHEKHAR S, GUPTA N, KIRUBAKARAN R，et al. Oral nifedipine versus intravenous labetalol for severe hypertension during pregnancy: a systematic review and meta-analysis[J]. BJOG，2016，123(1):40-47. DOI：10.1111/1471-0528.13463.
[27]	TOLCHER M C, FOX K A, SANGI-HAGHPEYKAR H，et al. Intravenous labetalol versus oral nifedipine for acute hypertension in pregnancy: effects on cerebral perfusion pressure[J]. Am J Obstet Gynecol，2020，223(3):441.e1-441.e8. DOI：10.1016/j.ajog.2020.06.018.
[28]	EASTERLING T, MUNDLE S, BRACKEN H，et al. Oral antihypertensive regimens （nifedipine retard，labetalol，and methyldopa） for management of severe hypertension in pregnancy: an open-label，randomised controlled trial[J]. Lancet，2019，394(10203):1011-1021. DOI：10.1016/S0140-6736(19)31282-6.
[29]	MCMAHON C G. Current diagnosis and management of erectile dysfunction[J]. Med J Aust，2019，210(10):469-476. DOI：10.5694/mja2.50167.
[30]	VIIGIMAA M, VLACHOPOULOS C, DOUMAS M，et al. Update of the position paper on arterial hypertension and erectile dysfunction[J]. J Hypertens，2020，38(7):1220-1234. DOI：10.1097/HJH.0000000000002382.
[31]	ALHABEEB W, MRABETI S, ABDELSALAM A A I. Therapeutic properties of highly selective β-blockers with or without additional vasodilator properties: focus on bisoprolol and nebivolol in patients with cardiovascular disease[J]. Cardiovasc Drugs Ther，2022，36(5):959-971. DOI：10.1007/s10557-021-07205-y.
[32]	MANOLIS A, DOUMAS M, FERRI C，et al. Erectile dysfunction and adherence to antihypertensive therapy: focus on β-blockers[J]. Eur J Intern Med，2020，81:1-6. DOI：10.1016/j.ejim.2020.07.009.
[33]	SHARP R P, GALES B J. Nebivolol versus other beta blockers in patients with hypertension and erectile dysfunction[J]. Ther Adv Urol，2017，9(2):59-63. DOI：10.1177/1756287216685027.
[34]	国家卫生计生委合理用药专家委员会，中国医师协会高血压专业委员会. 高血压合理用药指南（第2版）[J]. 中国医学前沿杂志（电子版），2017，9(7):28-126. DOI：10.12037/YXQY.2017.07-07.
[35]	SAMPLASKI M K, NANGIA A K. Adverse effects of common medications on male fertility[J]. Nat Rev Urol，2015，12(7):401-413. DOI：10.1038/nrurol.2015.145.
[36]	TERENTES-PRINTZIOS D, IOAKEIMIDIS N, ROKKAS K，et al. Interactions between erectile dysfunction，cardiovascular disease and cardiovascular drugs[J]. Nat Rev Cardiol，2022，19(1):59-74. DOI：10.1038/s41569-021-00593-6.
[37]	BANIHANI S A. Effect of captopril on semen quality[J]. Andrologia，2017，49(4). DOI：10.1111/and.12641.
[38]	MORAKINYO A O, IRANLOYE B O, DARAMOLA A O，et al. Antifertility effect of calcium channel blockers on male rats: association with oxidative stress[J]. Adv Med Sci，2011，56(1):95-105. DOI：10.2478/v10039-011-0018-y.
[39]	SANSONE A, DI DATO C, DE ANGELIS C，et al. Smoke，alcohol and drug addiction and male fertility[J]. Reprod Biol Endocrinol，2018，16(1):3. DOI：10.1186/s12958-018-0320-7.